A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis
NCT07845487
This study is recruiting at 24 US sites in 13 states, according to its ClinicalTrials.gov record last updated .
Summary
The ASCENTRA-UC study is a phase 2 study testing PALI-2108 in patients with moderate to severe ulcerative colitis. Doses of drug will be compared against a placebo to see how well it works, how safe it is, and how the body responds to it.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Ulcerative Colitis (UC)
- Severe Ulcerative Colitis
- Moderate Ulcerative Colitis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Palisade Bio
- Last updated on ClinicalTrials.gov
- September 29, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Site US-022 · Sun City, AZ
Florida · 1
- Site US-026 · Orlando, FL
Illinois · 3
- Site US-005 · Des Plaines, IL
- Site US-007 · Glenview, IL
- Site US-020 · Gurnee, IL
Louisiana · 1
- Site US-011 · Mandeville, LA
Missouri · 1
- Site US-006 · St Louis, MO
New Jersey · 1
- Site US-014 · Clifton, NJ
New York · 2
- Site US-002 · Albany, NY
- Site US-016 · Rochester, NY
Ohio · 3
- Site US-025 · Brunswick, OH
- Site US-023 · Dayton, OH
- Site US-027 · Westlake, OH
Rhode Island · 1
- Site US-019 · Providence, RI
Tennessee · 1
- Site US-003 · Cordova, TN
Texas · 6
- Site US-024 · Garland, TX
- Site US-009 · Georgetown, TX
- Site US-030 · Houston, TX
- Site US-015 · Lubbock, TX
- Site US-017 · Mansfield, TX
- Site US-001 · Southlake, TX
Virginia · 1
- Site US-013 · Richmond, VA
Washington · 2
- Site US-021 · Bellevue, WA
- Site US-029 · Tacoma, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.